PARCOPA Drug Patent Profile
✉ Email this page to a colleague
When do Parcopa patents expire, and when can generic versions of Parcopa launch?
Parcopa is a drug marketed by Ucb Inc and is included in one NDA.
The generic ingredient in PARCOPA is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Parcopa
A generic version of PARCOPA was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28th, 1992.
Summary for PARCOPA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 6 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PARCOPA at DailyMed |
Recent Clinical Trials for PARCOPA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Northwestern Medical Group | Phase 2 |
National Institutes of Health (NIH) | Phase 2 |
Northwestern University | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for PARCOPA
US Patents and Regulatory Information for PARCOPA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ucb Inc | PARCOPA | carbidopa; levodopa | TABLET, ORALLY DISINTEGRATING;ORAL | 076699-001 | Aug 27, 2004 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Ucb Inc | PARCOPA | carbidopa; levodopa | TABLET, ORALLY DISINTEGRATING;ORAL | 076699-002 | Aug 27, 2004 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Ucb Inc | PARCOPA | carbidopa; levodopa | TABLET, ORALLY DISINTEGRATING;ORAL | 076699-003 | Aug 27, 2004 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for PARCOPA
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Amneal Pharma Europe Ltd | Numient | levodopa, carbidopa | EMEA/H/C/002611 Symptomatic treatment of adult patients with Parkinson’s disease |
Withdrawn | no | no | no | 2015-11-19 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |